Featured Research

from universities, journals, and other organizations

Genetic predictors of fatigue for prostate cancer patients receiving androgen deprivation therapy

Date:
October 26, 2012
Source:
Moffitt Cancer Center
Summary:
Researchers have found that men with prostate cancer who receive androgen deprivation therapy may predictably suffer from fatigue if they have single nucleotide polymorphisms in three pro-inflammatory genes. The discovery highlights the importance of personalized medicine, in which therapies are tailored to a patient’s genetic profile.

Researchers at Moffitt Cancer Center and the University of South Florida have found that men with prostate cancer who receive androgen deprivation therapy may predictably suffer from fatigue if they have single nucleotide polymorphisms in three pro-inflammatory genes. The discovery highlights the importance of personalized medicine, in which therapies are tailored to a patient's genetic profile.

Related Articles


The study appears in the October issue of Brain, Behavior, and Immunity.

"Few studies have examined the role of genes in cancer-related fatigue and none, to our knowledge, have examined genetic variation related to androgen deprivation therapy," said study co-principal investigator Heather S.L. Jim, Ph.D., assistant member of the Health Outcomes and Behavior Program. "We found that prostate cancer patients who carry the variants of the IL6 and TNFA genes and are treated with androgen deprivation therapy are susceptible to heightened fatigue."

Evidence from prostate cancer studies suggests that pro-inflammatory cytokines, which have been linked to fatigue in cancer patients, are influenced by testosterone. At the same time, testosterone inhibits IL6 gene expression. Androgen deprivation therapy restricts testosterone.

"The goal of our study was to examine whether single nucleotide polymorphisms in genes that regulate pro-inflammatory cytokines can predict changes in fatigue in men receiving androgen deprivation therapy," said co-principal investigator Paul B. Jacobsen, Ph.D., associate center director for Cancer Prevention & Control at Moffitt. "We hypothesized that patients displaying variants at these sites would display greater increases in fatigue following initiation of androgen deprivation therapy."

The researchers found that patients with a greater number of variants reported greater increases in fatigue and of longer duration.

"It is still unclear why IL6 and TNFA genotypes affected some aspects of fatigue but not others," Jim said. "While the single nucleotide polymorphisms found in our study were located in predicted transcription factor binding sites that regulate gene expression, a single gene can have many regulatory sites scattered across the genome."

The authors speculated that new single nucleotide polymorphisms may be uncovered that will help to clarify the mechanisms of inflammatory gene transcription as they relate to fatigue in cancer patients. Preliminary findings from this study "represent an important first step in identifying genetic variation as a predictor of fatigue secondary to androgen deprivation therapy," the researchers concluded.

"Early identification of patients with genetic risk factors can enable clinicians to provide timely interventions, behavioral or pharmacologic, to prevent or reduce fatigue," Jacobsen said. "This goal is consistent with personalized cancer treatment tailored to individual gene profiles to maximize benefit and minimize side effects."

The study was funded by two grants from the National Cancer Institute: NCI R01-CA132803 and NCI K07-CA138499.

About Moffitt Cancer Center Located in Tampa, Moffitt is one of only 41 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt's excellence in research, its contributions to clinical trials, prevention and cancer control. Since 1999, Moffitt has been listed in U.S. News & World Report as one of "America's Best Hospitals" for cancer. With more than 4,200 employees, Moffitt has an economic impact on the state of nearly $2 billion. For more information, visit MOFFITT.org, and follow the Moffitt momentum on Facebook, twitter and YouTube.

Media release by Florida Science Communications

###


Story Source:

The above story is based on materials provided by Moffitt Cancer Center. Note: Materials may be edited for content and length.


Journal Reference:

  1. Heather S.L. Jim, Jong Y. Park, Jennifer Permuth-Wey, Maria A. Rincon, Kristin M. Phillips, Brent J. Small, Paul B. Jacobsen. Genetic predictors of fatigue in prostate cancer patients treated with androgen deprivation therapy: Preliminary findings. Brain, Behavior, and Immunity, 2012; 26 (7): 1030 DOI: 10.1016/j.bbi.2012.03.001

Cite This Page:

Moffitt Cancer Center. "Genetic predictors of fatigue for prostate cancer patients receiving androgen deprivation therapy." ScienceDaily. ScienceDaily, 26 October 2012. <www.sciencedaily.com/releases/2012/10/121026124839.htm>.
Moffitt Cancer Center. (2012, October 26). Genetic predictors of fatigue for prostate cancer patients receiving androgen deprivation therapy. ScienceDaily. Retrieved November 28, 2014 from www.sciencedaily.com/releases/2012/10/121026124839.htm
Moffitt Cancer Center. "Genetic predictors of fatigue for prostate cancer patients receiving androgen deprivation therapy." ScienceDaily. www.sciencedaily.com/releases/2012/10/121026124839.htm (accessed November 28, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, November 28, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Rural India's Low-Cost Sanitary Pad Revolution

Rural India's Low-Cost Sanitary Pad Revolution

AFP (Nov. 28, 2014) — One man hopes his invention -– a machine that produces cheap sanitary pads –- will help empower Indian women. Duration: 01:51 Video provided by AFP
Powered by NewsLook.com
Research on Bats Could Help Develop Drugs Against Ebola

Research on Bats Could Help Develop Drugs Against Ebola

AFP (Nov. 28, 2014) — In Africa's only biosafety level 4 laboratory, scientists have been carrying out experiments on bats to understand how virus like Ebola are being transmitted, and how some of them resist to it. Duration: 01:18 Video provided by AFP
Powered by NewsLook.com
WHO Says Male Ebola Survivors Should Abstain From Sex

WHO Says Male Ebola Survivors Should Abstain From Sex

Newsy (Nov. 28, 2014) — WHO cites four studies that say Ebola can still be detected in semen up to 82 days after the onset of symptoms. Video provided by Newsy
Powered by NewsLook.com
Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins